NASDAQ:PHIO

Phio Pharmaceuticals (PHIO) Stock Price, News & Analysis

Phio Pharmaceuticals logo
$0.72 -0.04 (-4.65%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.72 +0.00 (+0.11%)
As of 07:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Phio Pharmaceuticals Stock (NASDAQ:PHIO)

Advanced

Key Stats

Today's Range
$0.70
▼
$0.75
50-Day Range
$0.72
▼
$1.03
52-Week Range
$0.70
▼
$1.88
Volume
65,486 shs
Average Volume
63,436 shs
Market Capitalization
$8.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00
Consensus Rating
Hold

Company Overview

Phio Pharmaceuticals is a clinical-stage biotechnology company developing treatments based on its INTASYL platform, a technology for delivering RNA interference compounds into cells to reduce the activity of selected genes. The company focuses on potential therapies for cancer, particularly approaches intended to strengthen the body’s immune response to tumors.

Its pipeline includes candidates designed to target genes involved in immune regulation and tumor biology. These investigational treatments are being developed for solid tumors; they are not approved for commercial use.

Previously known as RXi Pharmaceuticals, the company adopted the Phio Pharmaceuticals name in 2019. It is based in Marlborough, Massachusetts.

AI Generated. May Contain Errors.

Phio Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
92nd Percentile Overall Score

PHIO MarketRank™: 
4.60112059765 of 5 stars

Phio Pharmaceuticals scored higher than 92% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Phio Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    Phio Pharmaceuticals has a consensus price target of $14.00, representing about 1,852.0% upside from its current price of $0.72.

  • Amount of Analyst Coverage

    Phio Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Phio Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Phio Pharmaceuticals are expected to grow in the coming year, from ($1.47) to ($0.77) per share.

  • Price to Book Value per Share Ratio

    Phio Pharmaceuticals has a P/B Ratio of 1.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.75% of the float of Phio Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Phio Pharmaceuticals has a short interest ratio ("days to cover") of 1.49, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Phio Pharmaceuticals has recently decreased by 36.69%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Phio Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Phio Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Phio Pharmaceuticals has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Phio Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    5 people have searched for PHIO on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Phio Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Cluster Insider Buying

    4 insiders have purchased shares of Phio Pharmaceuticals in the last three months. Multiple insiders buying is a strong bullish signal.

  • Net Insider Buying

    Over the last three months, insiders have purchased a net $86,424.00 in company stock, which represents 1.0084% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Phio Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $86,424.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    3.52% of the stock of Phio Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    57.31% of the stock of Phio Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Phio Pharmaceuticals' insider trading history.
Receive PHIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PHIO Stock News Headlines

The Democrats can’t stop this
Porter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century.tc pixel
See More Headlines

PHIO Stock Analysis - Frequently Asked Questions

Phio Pharmaceuticals' stock was trading at $1.05 at the beginning of the year. Since then, PHIO stock has decreased by 31.7% and is now trading at $0.7172.

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) announced its earnings results on Thursday, November, 5th. The company reported ($0.36) EPS for the quarter, hitting the consensus estimate of ($0.36).

Phio Pharmaceuticals's stock reverse split on Friday, July 5th 2024.The 1-9 reverse split was announced on Friday, July 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split.

Shares of PHIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Phio Pharmaceuticals investors own include NVIDIA (NVDA), NIO (NIO), QuantumScape (QS), Senseonics (SENS), Nano Dimension (NNDM), Ford Motor (F) and Ocugen (OCGN).

Company Calendar

Last Earnings
11/05/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:PHIO
CIK
1533040
Employees
6
Year Founded
2011

Price Target and Rating

High Price Target
$14.00
Low Price Target
$14.00
Potential Upside/Downside
+1,852.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.70 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-101.48%
Return on Assets
-90.96%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.19
Quick Ratio
4.19

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.72 per share
Price / Book
1.00

Miscellaneous

Outstanding Shares
11,950,000
Free Float
11,531,000
Market Cap
$8.57 million
Optionable
Not Optionable
Beta
0.93

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:PHIO) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners